TEM is a data-rich platform that recently clinched a $200 million deal with AstraZeneca. TEM’s main bet is now on AI for ...

Ambry Genetics was the first commercial laboratory to begin offering clinical diagnostic exome sequencing testing in 2011 3, which may bring new hope to thousands of patients and families searching ...

Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting revenue and backlog. The AI precision medicine company grew core revenues 32% ...

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The company reports a first-quarter adjusted loss of 24 cents per share, beating analyst ...

Major acquisitions and partnerships have played a key role in Tempus AI’s market growth, solidifying its position in healthcare AI. The Ambry Genetics acquisition expanded its genomics division ...

Despite filing a fourth-quarter and year-end 2024 earnings report that the CEO described as "fantastic" yesterday afternoon, Tempus AI shares fell overnight and a major investment house downgraded ...

Tempus AI reports fourth-quarter revenue of $200.68 million, missing estimates of $203.12 million. Tempus reports a fourth-quarter adjusted loss of 18 cents per share, beating analyst estimates ...

Key Points About Article Just a few weeks ago, Tempus AI (NASDAQ: TEM) rocketed from about 44% higher.All on news it just acquired Ambry Genetics and on news, Nancy Pelosi took a stake in the TEM ...